ASP Isotopes (NASDAQ:ASPI) CFO Sells $145,218.72 in Stock

ASP Isotopes Inc. (NASDAQ:ASPI) CFO Heather Kiessling sold 23,124 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $6.28, for a total transaction of $145,218.72. Following the sale, the chief financial officer owned 1,526,252 shares of the company’s stock, valued at $9,584,862.56. This trade represents a 1.49% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Heather Kiessling also recently made the following trade(s):

• On Wednesday, April 15th, Heather Kiessling sold 23,124 shares of ASP Isotopes stock. The shares were sold at an average price of $5.48, for a total value of $126,719.52.

ASP Isotopes Stock Performance

Shares of ASP Isotopes stock traded down $0.54 on Thursday, hitting $5.63. The stock had a trading volume of 4,836,362 shares, compared to its average volume of 4,870,282. The stock has a market cap of $708.82 million, a price-to-earnings ratio of -2.71 and a beta of 3.51. The company has a quick ratio of 4.37, a current ratio of 4.39 and a debt-to-equity ratio of 0.69. ASP Isotopes Inc. has a twelve month low of $3.92 and a twelve month high of $14.49. The business’s 50 day moving average is $6.25 and its two-hundred day moving average is $5.90.

ASP Isotopes (NASDAQ:ASPI) last released its quarterly earnings results on Wednesday, May 20th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.28) by $0.06. The business had revenue of $8.36 million during the quarter, compared to analysts’ expectations of $3.68 million. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on ASPI. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research report on Wednesday, June 24th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $11.00 price target on shares of ASP Isotopes in a research report on Tuesday, April 14th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $13.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ASPI. State of Wyoming bought a new stake in ASP Isotopes during the first quarter worth about $29,000. Quantbot Technologies LP acquired a new position in shares of ASP Isotopes in the 3rd quarter valued at approximately $34,000. BNP Paribas Financial Markets lifted its holdings in shares of ASP Isotopes by 84.9% during the 2nd quarter. BNP Paribas Financial Markets now owns 5,549 shares of the company’s stock worth $41,000 after acquiring an additional 2,548 shares during the period. Stephens Inc. AR bought a new stake in shares of ASP Isotopes during the 1st quarter worth approximately $44,000. Finally, Broadhurst Jeffrey B acquired a new stake in shares of ASP Isotopes during the 1st quarter worth approximately $44,000. Institutional investors and hedge funds own 16.80% of the company’s stock.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.